# Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

Clinical trial · COMPASS Pathways

- Archive id: nct:NCT07570654
- Published: 2026-05-06
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT07570654
- Source URL: https://clinicaltrials.gov/study/NCT07570654
- Provenance: clinicaltrials

## Abstract

The Redefine Study (COMP202) is testing COMP360 to see if it may reduce post-traumatic stress disorder (PTSD) symptoms when administered alongside monitoring and support from a trained study team. COMP360 is a lab-made form of the naturally occurring chemical compound psilocybin.

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- acronym: Redefine
- status: RECRUITING
- phase: PHASE2, PHASE3
- study type: INTERVENTIONAL
- enrollment: 300
- sponsor: COMPASS Pathways
- conditions: PTSD - Post Traumatic Stress Disorder; PTSD; PTSD Symptoms; PTSD, Post Traumatic Stress Disorder
- interventions: DRUG: COMP360 psilocybin
- start date: 2026-09-01
- start date type: ESTIMATED
- primary completion date: 2028-11-01
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [Novel Psychiatric Therapeutics](https://space-kitty.com/topics/psychiatric-therapeutics)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.